[HTML][HTML] Telomere maintenance mechanisms in cancer

T Bordeira Gaspar, A Sá, JM Lopes… - Genes, 2018 - mdpi.com
Tumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere
shortening, an inevitable process due to successive cell divisions. In most tumour cells …

[HTML][HTML] Novel targeted therapies for metastatic thyroid cancer—a comprehensive review

M Al-Jundi, S Thakur, S Gubbi, J Klubo-Gwiezdzinska - Cancers, 2020 - mdpi.com
The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

[HTML][HTML] Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy

Y Liu, J Wang, X Hu, Z Pan, T Xu, J Xu, L Jiang… - Drug Resistance …, 2023 - Elsevier
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

[HTML][HTML] Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy

J Liu, Y Liu, Y Lin, J Liang - Endocrinology and Metabolism, 2019 - ncbi.nlm.nih.gov
The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease

M Melo, A Gaspar da Rocha, R Batista… - The Journal of …, 2017 - academic.oup.com
Context Little is known about the frequency of key mutations in thyroid cancer metastases
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …

The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer

J Liu, R Liu, X Shen, G Zhu, B Li… - Journal of Nuclear …, 2020 - Soc Nuclear Med
BRAF V600E and TERT promoter mutations, particularly their genetic duet, are well known
to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of …

[HTML][HTML] Redifferentiation of radioiodine-refractory thyroid cancers

C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - erc.bioscientifica.com
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

[HTML][HTML] Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis

J Yang, Y Gong, S Yan, H Chen, S Qin, R Gong - Endocrine, 2020 - Springer
Background The association between telomerase reverse transcriptase (TERT) promoter
mutations and some clinical behaviors in thyroid cancer remains controversial and requires …

[HTML][HTML] Telomerase reverse transcriptase (TERT) regulation in thyroid cancer: a review

BA McKelvey, CB Umbricht, MA Zeiger - Frontiers in Endocrinology, 2020 - frontiersin.org
Telomerase reverse transcriptase (TERT) is the catalytic subunit of the enzyme telomerase
and is essential for telomerase activity. Upregulation of TERT expression and resulting …

The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer

J Cao, X Zhu, Y Sun, X Li, C Yun, W Zhang - European Journal of Nuclear …, 2022 - Springer
Abstract Objective The BRAF V600E and TERT promoter mutations are well known to be
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …